Galectin Therapeutics (GALT) Competitors $5.37 -0.57 (-9.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.50 +0.13 (+2.42%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. SION, STOK, MLYS, PHAR, NUVB, SYRE, CRON, ORIC, ATAI, and PRAXShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Sionna Therapeutics (SION), Stoke Therapeutics (STOK), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), Nuvation Bio (NUVB), Spyre Therapeutics (SYRE), Cronos Group (CRON), Oric Pharmaceuticals (ORIC), atai Life Sciences (ATAI), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Sionna Therapeutics Stoke Therapeutics Mineralys Therapeutics Pharming Group Nuvation Bio Spyre Therapeutics Cronos Group Oric Pharmaceuticals atai Life Sciences Praxis Precision Medicines Sionna Therapeutics (NASDAQ:SION) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability. Do institutionals and insiders hold more shares of SION or GALT? 11.7% of Galectin Therapeutics shares are held by institutional investors. 3.9% of Sionna Therapeutics shares are held by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, SION or GALT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AGalectin TherapeuticsN/AN/A-$47.05M-$0.64-8.39 Do analysts recommend SION or GALT? Sionna Therapeutics currently has a consensus price target of $38.00, suggesting a potential upside of 66.45%. Galectin Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 11.73%. Given Sionna Therapeutics' higher possible upside, research analysts clearly believe Sionna Therapeutics is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SION or GALT more profitable? Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Galectin Therapeutics N/A N/A -225.32% Does the media prefer SION or GALT? In the previous week, Sionna Therapeutics had 10 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Sionna Therapeutics and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.41 beat Sionna Therapeutics' score of 0.76 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySionna Therapeutics beats Galectin Therapeutics on 5 of the 9 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$380.52M$2.59B$5.87B$10.14BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-8.3923.5374.5225.93Price / SalesN/A699.42549.78198.13Price / CashN/A171.1637.5660.44Price / Book-3.205.3712.166.29Net Income-$47.05M$32.95M$3.28B$270.77M7 Day Performance16.74%1.28%0.87%3.88%1 Month Performance46.32%6.09%4.96%4.88%1 Year Performance87.11%-2.15%60.74%26.01% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics1.3317 of 5 stars$5.37-9.6%$6.00+11.7%+98.2%$380.52MN/A-8.399Positive NewsGap UpHigh Trading VolumeSIONSionna Therapeutics2.8099 of 5 stars$24.62-4.3%$38.50+56.4%N/A$1.09BN/A0.0035Gap UpSTOKStoke Therapeutics3.9686 of 5 stars$19.76-0.1%$25.57+29.4%+71.1%$1.08B$36.56M23.25100Positive NewsMLYSMineralys Therapeutics3 of 5 stars$15.48+1.7%$34.40+122.2%+220.1%$1.03BN/A-4.3528Analyst ForecastPHARPharming Group2.0718 of 5 stars$14.84+1.7%$30.00+102.2%+95.1%$1.02B$297.20M-114.15280News CoveragePositive NewsShort Interest ↑Gap UpNUVBNuvation Bio2.6187 of 5 stars$2.98+1.9%$7.33+146.5%+3.0%$1.02B$7.87M-4.7260Gap DownSYRESpyre Therapeutics2.3307 of 5 stars$16.49-1.4%$53.40+223.8%-45.0%$996.01M$890K-4.8573Positive NewsCRONCronos Group2.517 of 5 stars$2.60flatN/A+17.1%$995.90M$117.61M52.00450ORICOric Pharmaceuticals4.5439 of 5 stars$10.23+2.0%$17.63+72.3%+19.0%$993.57MN/A-5.4180Positive NewsATAIatai Life Sciences2.8896 of 5 stars$4.58-1.5%$11.25+145.6%+276.4%$981.67M$310K-6.6480Positive NewsPRAXPraxis Precision Medicines2.4564 of 5 stars$45.54-1.0%$85.88+88.6%-35.8%$958.42M$8.55M-3.71110Positive News Related Companies and Tools Related Companies SION Alternatives STOK Alternatives MLYS Alternatives PHAR Alternatives NUVB Alternatives SYRE Alternatives CRON Alternatives ORIC Alternatives ATAI Alternatives PRAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts